Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey.
Sophia Quirke-McFarlaneJohn WeinmanEmma S CookZenas Zee Ngai YiuNick DandSinead M LanganKatie BechmanTeresa TsakokKayleigh J MasonHelen McAteerFreya MeynellBolaji CokerAlexandra VincentDominic UrmstonAmber VestyJade KellyCamille LancelotLucy MoorheadInes A BarbosaHerve BachelezFrancesca CaponClaudia R ContrerasClaudia De La CruzPaola Di MeglioPaolo GisondiDenis JullienJo LambertLuigi NaldiLluís PuigPhyllis SpulsTiago TorresRichard Bruce WarrenHoseah WaweruJames B GallowayChristopher E M GriffithsJonathan N BarkerKatherine JonesCatherine H SmithSatveer K Mahilnull nullPublished in: The British journal of dermatology (2022)
These data indicate substantial non-adherence to immune-modifying therapy in people with psoriasis during the pandemic, with attenuation of the association with mental health after adjusting for confounders. Future research in larger populations should further explore pandemic-specific drivers of treatment non-adherence. Clear communication of the reassuring findings from population-based research regarding immune-modifying therapy-associated adverse COVID-19 risks to people with psoriasis is essential, to optimise adherence and disease outcomes.